CaPre omega-3 phospholipids: Phase II data

An open-label, dose-escalation, Canadian Phase II trial in over 230 patients showed that 4 g once-daily CaPre led to a significant reduction in mean triglyceride levels of 15.5% from baseline to week 4, which was an absolute mean improvement of 18.1% as compared to standard of care (SOC) with a lipid lowering therapy. At week 8, 4 g CaPre led to a mean reduction in triglyceride levels from baseline of 21.6% and an absolute mean improvement of 14.2% as compared to SOC. Additionally, 4 g CaPre reduced mean LDL by 8.3% and mean non-HDL by 14.3% from baseline to week 8. Furthermore, 4 g CaPre significantly increased HDL by 11.1% at week 4 compared to SOC. The company said the efficacy of CaPre increased with dose escalation. CaPre was safe with no serious adverse events reported. The trial evaluated 0.5, 1, 2 and 4 g CaPre. ...